Healthcare Multi-Agent AI Creates Ownership and Retirement Gaps That Standard Governance Frameworks Do Not Cover, arXiv Research Warns

What happened

Why it matters

• ·Healthcare organizations deploying multi-agent AI systems face compounded regulatory exposure because failures in agent interaction chains may not be traceable to a single accountable system or owner, complicating obligations under the California Health Care Services AI Act Disclosure Requirements and analogous frameworks that presuppose identifiable, discrete AI decision points.
• ·The absence of formal agent retirement governance creates operational risk that compounds over time: agents with outdated permissions, stale data access, or superseded clinical logic may continue operating indefinitely if no decommissioning trigger exists, a gap that directly undermines model lifecycle controls and exposes organizations to audit findings.
• ·Compliance teams in healthcare and adjacent sectors lack standard controls for multi-agent trust hierarchies and inter-agent permission flows, meaning that a single compromised or misbehaving agent can propagate errors or unauthorized actions across an entire deployment without triggering existing monitoring thresholds.

Governance controls affected

What to do now

• ☐Audit all currently deployed AI systems in clinical and operational workflows to identify any multi-agent configurations, including orchestration layers, retrieval-augmented pipelines, and automated handoff chains, and assign a named owner to each agent.
• ☐Review existing agent permission inventories against the framework's requirement that permissions be explicitly bounded per agent, and flag any agents operating with inherited or default permissions that have not been formally approved.
• ☐Establish formal retirement criteria for each deployed agent, including triggers based on model version changes, data access expiration, or clinical guideline updates, and document these criteria in your model change inventory.
• ☐Map inter-agent communication flows and delegation chains and assess whether existing audit log standards capture interactions between agents rather than only individual agent outputs.
• ☐Assess whether your current AI risk classification process distinguishes between single-model deployments and multi-agent systems, and update your intake and approval workflow to require a separate governance review for any multi-agent configuration.

What to watch next

Healthcare and life sciences compliance teams should monitor whether the FDA AI/ML Software as Medical Device Guidance is updated to address multi-agent configurations explicitly, as the framework's distributed accountability model does not map cleanly onto current software-as-a-medical-device review processes. The IMDA Model AI Governance Framework for Agentic AI offers the closest existing policy analog to the ownership and permission-bounding requirements proposed in this research, and any forthcoming updates to that framework may signal the direction of binding healthcare-specific rules. Organizations should also watch for enforcement actions or audit findings in the CMS and state health agency contexts that target agent sprawl or undocumented AI handoff chains, as regulators are increasingly scrutinizing AI-assisted clinical decision workflows as demonstrated by the CMS WISeR pilot scrutiny.